EU Regulator Approves Lenacapavir, a Long-Acting Injectable HIV Prevention Drug
The European Medicines Agency (EMA) has issued a positive recommendation for lenacapavir, a twice-yearly injectable drug developed by Gilead Sciences, for pre-exposure prophylaxis (PrEP) against HIV-1 infection. The approval marks a major advancement in HIV prevention, offering the longest-lasting protection currently available. Lenacapavir, marketed as Yeytuo in Europe, is already approved for HIV treatment and […]
Continue Reading